comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-03 00:39:45 - browse：934

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Has Bernie Sanders reached the limit of his pharma bullying effort?

WSS

AltruBio raises $225 million to develop ulcerative colitis drug

Novel spinal cord stimulator treats paralysis without surgery

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Novel spinal cord stimulator treats paralysis without surgery

Stanford president to resign after investigation of research

Is it ever OK for doctors to lie to their patients?

focus

comprehensive

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

As health system earnings go up, health insurance stocks go down

Walensky prepares to leave CDC — and Congress — behind

Lawmakers grill UnitedHealth CEO on Change cyberattack

The high cost of giving birth even with insurance

Man who had jail sentence commuted by Trump arrested again

What does generative AI mean for health care? We asked experts

Stanford president to resign after investigation of research

Medical leaders decry Supreme Court decision on affirmative action

Deliver public health messages at the right time

focus

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

DOJ, FTC to increase scrutiny of all types of health care mergers

How dance can help health care workers heal from trauma

Ebola public health emergency is over, WHO declares

As health system earnings go up, health insurance stocks go down

Can gargling with Listerine treat gonorrhea of the mouth?

focus

explore

leisure time

focus